The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2024 | Insights into ongoing research on BTK degraders for lymphoid malignancies
Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, discusses the emergence of BTK degraders in the treatment landscape of lymphoid malignancies. Prof. Danilov highlights the results from an ongoing Phase I trial (NCT05131022) of NX-5948 in heavily pretreated patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). This agent had a promising 70% response rate and an impressive safety profile with no major adverse events reported. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
